Consensus guidelines from the American Society of Peritoneal Surface Malignancies on standardizing the delivery of hyperthermic intraperitoneal chemotherapy (HIPEC) in colorectal cancer patients in the United States Journal Article

  

Authors:	Turaga, K.; Levine, E.; Barone, R.; Sticca, R.; Petrelli, N.; Lambert, L.; Nash, G.; Morse, M.; Adbel-Misih, R.; Alexander, H. R.; Attiyeh, F.; Bartlett, D.; Bastidas, A.; Blazer, T.; Chu, Q.; Chung, K.; Dominguez-Parra, L.; Espat, N. J.; Foster, J.; Fournier, K.; Garcia, R.; Goodman, M.; Hanna, N.; Harrison, L.; Hoefer, R.; Holtzman, M.; Kane, J.; Labow, D.; Li, B.; Lowy, A.; Mansfield, P.; Ong, E.; Pameijer, C.; Pingpank, J.; Quinones, M.; Royal, R.; Salti, G.; Sardi, A.; Shen, P.; Skitzki, J.; Spellman, J.; Stewart, J.; Esquivel, J.
Article Title:	Consensus guidelines from the American Society of Peritoneal Surface Malignancies on standardizing the delivery of hyperthermic intraperitoneal chemotherapy (HIPEC) in colorectal cancer patients in the United States
Abstract:	Background: The American Society of Peritoneal Surface Malignancies (ASPSM) is a consortium of cancer centers performing cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (HIPEC). This is a position paper from the ASPSM on the standardization of the delivery of HIPEC. Methods: A survey was conducted of all cancer centers performing HIPEC in the United States. We attempted to obtain consensus by the modified method of Delphi on seven key HIPEC parameters: (1) method, (2) inflow temperature, (3) perfusate volume, (4) drug, (5) dosage, (6) timing of drug delivery, and (7) total perfusion time. Statistical analysis was performed using nonparametric tests. Results: Response rates for ASPSM members (n = 45) and non-ASPSM members (n = 24) were 89 and 33 %, respectively. Of the responders from ASPSM members, 95 % agreed with implementing the proposal. Majority of the surgical oncologists favored the closed method of delivery with a standardized dual dose of mitomycin for a 90-min chemoperfusion for patients undergoing cytoreductive surgery for peritoneal carcinomatosis of colorectal origin. Conclusions: This recommendation on a standardized delivery of HIPEC in patients with colorectal cancer represents an important first step in enhancing research in this field. Studies directed at maximizing the efficacy of each of the seven key elements will need to follow. © 2013 Society of Surgical Oncology.
Keywords:	cancer chemotherapy; united states; cancer patient; colorectal cancer; cytoreductive surgery; practice guideline; cancer center; population research; peritoneum metastasis; drug delivery system; carcinomatosis; hyperthermic intraperitoneal chemotherapy; human; article; american society of peritoneal surface malignancies
Journal Title:	Annals of Surgical Oncology
Volume:	21
Issue:	5
ISSN:	1068-9265
Publisher:	Springer
Date Published:	2014-05-01
Start Page:	1501
End Page:	1505
Language:	English
DOI:	10.1245/s10434-013-3061-z
PROVIDER:	scopus
PUBMED:	23793364
DOI/URL:	http://www.scopus.com/inward/record.url?eid=2-s2.0-84898852205&partnerID=40&md5=d47caa83f1c7ac0fa054f25116f3b366
Notes:	Ann. Surg. Oncol. -- Export Date: 2 June 2014 -- CODEN: ASONF -- Source: Scopus

https://synapse.mskcc.org/synapse/works/has_related_data_chk/51891